Eben Tessari
Founder chez KINIKSA PHARMACEUTICALS, LTD.
Fortune : 2 M $ au 31/03/2024
Profil
Eben P.
Tessari is the founder.
In 2015, he founded Kiniksa Pharmaceuticals Ltd.
and currently holds the title of Chief Operating Officer & Senior Vice President.
Prior to founding Kiniksa Pharmaceuticals Ltd., Mr. Tessari held former positions at Civitas Therapeutics, Inc. as Director-Business & Corporate Development from 2013 to 2014, and at Synageva BioPharma Corp.
as Senior Director & Head-Business Development from 2014 to 2015.
Mr. Tessari's education history includes a graduate degree from Boston University and Suffolk University, as well as an undergraduate degree from Northeastern University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/04/2024 | 126 024 ( 0,32% ) | 2 M $ | 31/03/2024 |
Postes actifs de Eben Tessari
| Sociétés | Poste | Début |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Founder | 01/07/2015 |
Anciens postes connus de Eben Tessari
| Sociétés | Poste | Fin |
|---|---|---|
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 01/07/2015 |
Civitas Therapeutics, Inc.
 Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Corporate Officer/Principal | 01/12/2014 |
Formation de Eben Tessari
| Boston University | Graduate Degree |
| Suffolk University | Graduate Degree |
| Northeastern University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Civitas Therapeutics, Inc.
Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Health Technology |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
| Kiniksa Pharmaceuticals Ltd. |
